Latest News from: Sanford Burnham Prebys

Filters close
Newswise: How a single protein could unlock age-related vision loss
Released: 6-Sep-2022 5:05 PM EDT
How a single protein could unlock age-related vision loss
Sanford Burnham Prebys

Research led by Sanford Burnham Prebys professor Francesca Marassi, Ph.D., is helping to reveal the molecular secrets of macular degeneration, which causes almost 90% of all age-related vision loss. The study, published recently in the Biophysical Journal, describes the flexible structure of a key blood protein involved in macular degeneration and other age-related diseases, such as Alzheimer’s and atherosclerosis.

Newswise: Inhibiting key metabolic enzyme shows promise against melanoma
29-Aug-2022 11:00 AM EDT
Inhibiting key metabolic enzyme shows promise against melanoma
Sanford Burnham Prebys

Researchers at Sanford Burnham Prebys, led by Ze’ev Ronai, Ph.D., have shown for the first time that inhibiting a key metabolic enzyme selectively kills melanoma cells and stops tumor growth. Published in Nature Cell Biology, these findings could lead to a new class of drugs to selectively treat melanoma, the most severe form of skin cancer.

Newswise: Peter Adams and Bing Ren awarded $10.6M to create atlas of aging cells
Released: 16-Aug-2022 12:40 PM EDT
Peter Adams and Bing Ren awarded $10.6M to create atlas of aging cells
Sanford Burnham Prebys

Peter Adams, Ph.D., and Bing Ren, Ph.D., have been awarded a new grant from the National Institutes of Health (NIH) to join a multi-institution initiative studying the process of aging.

Newswise: Jianhua Zhao awarded $2.4M to reveal cancer targets through atomic-resolution imaging
Released: 2-Aug-2022 6:05 PM EDT
Jianhua Zhao awarded $2.4M to reveal cancer targets through atomic-resolution imaging
Sanford Burnham Prebys

Assistant Professor Jianhua Zhao, Ph.D., has been awarded a unique and competitive grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH). The five-year, $2.4 million grant aims to give researchers greater research flexibility to work on fundamental questions in biology.

Newswise: Timothy Huang awarded $2.8M to study well-known gene linked to Alzheimer’s disease
Released: 2-Aug-2022 6:05 PM EDT
Timothy Huang awarded $2.8M to study well-known gene linked to Alzheimer’s disease
Sanford Burnham Prebys

Timothy Huang, Ph.D., has been awarded $2.8 million by the National Institute on Aging (NIA) to continue his work on Alzheimer’s disease. The four-year project will use human stem cells transplanted into mice to determine the role of specific Alzheimer’s-related gene mutations in the brain.

Newswise: Brooke Emerling Awarded $2.3 Million to Demystify Breast Cancer Metabolism
Released: 27-Jun-2022 4:30 PM EDT
Brooke Emerling Awarded $2.3 Million to Demystify Breast Cancer Metabolism
Sanford Burnham Prebys

Brooke Emerling from Sanford Burnham Prebys has been awarded a new grant from the National Institutes of Health (NIH) to continue her work on cellular signaling in cancer. The four-year, $2.3 million project could accelerate the development of new therapies for a range of cancers, particularly metastatic breast cancer. It also offers an answer to a longstanding mystery in cancer metabolism.

Newswise: Tricking the body to treat breast cancer
Released: 15-Mar-2022 5:10 PM EDT
Tricking the body to treat breast cancer
Sanford Burnham Prebys

With the help of two new grants from the National Institutes of Health totaling more than $4.4 million, Sanford Burnham Prebys professor Charles Spruck, Ph.D., and his team are refining a cutting-edge breast cancer treatment.

Newswise: Against all odds, Rare Disease Day is back in San Diego
Released: 23-Feb-2022 4:25 PM EST
Against all odds, Rare Disease Day is back in San Diego
Sanford Burnham Prebys

The 2022 Rare Disease Day Symposium & CDG/NGLY1 Family Conference will take place February 25-27th at the Dana Hotel on Mission Bay in San Diego.

Newswise: Bioinformaticist Kevin Yip joins Sanford Burnham Prebys
Released: 9-Feb-2022 2:15 PM EST
Bioinformaticist Kevin Yip joins Sanford Burnham Prebys
Sanford Burnham Prebys

Bioinformaticist Kevin Yip, Ph.D., has joined Sanford Burnham Prebys as a professor, where he will collaborate with other faculty across the Institute on large-scale data analysis and develop new tools and models for computational biology.

   
Newswise: Research reveals why more Black women die from breast cancer
2-Feb-2022 2:00 PM EST
Research reveals why more Black women die from breast cancer
Sanford Burnham Prebys

New research from Sanford Burnham Prebys has revealed significant molecular differences between the breast cells of white and Black women that help explain why Black women experience higher breast cancer mortality. The findings, published in the journal Therapeutic Advances in Medical Oncology, suggest that changing current diagnostic and treatment strategies could help address the disparity.

Newswise: Sanford Burnham Prebys professor awarded $2.9 million to explore new answers to old questions in Alzheimer’s research
Released: 1-Feb-2022 9:00 AM EST
Sanford Burnham Prebys professor awarded $2.9 million to explore new answers to old questions in Alzheimer’s research
Sanford Burnham Prebys

Sanford Burnham Prebys professor Yu Yamaguchi has been awarded a $2.9 million grant from the National Institutes of Health to study the role of heparan sulfate (HS) in Alzheimer’s disease. HS is a structural molecule found in the scaffolding between cells that has been previously observed to influence the development of Alzheimer’s disease. However, the precise function it plays in the brain has not been studied closely.

Released: 18-Jan-2022 5:55 PM EST
New COVID-19 drug passes phase 2 clinical trial
Sanford Burnham Prebys

In a phase 2 clinical trial conducted by Avalo Therapeutics and supported by researchers from Sanford Burnham Prebys, a significantly higher proportion of hospitalized patients with COVID-19 remained alive and free of respiratory failure for 28 days after receiving treatment with a new antibody called CERC-002. Unlike other experimental COVID therapies, CERC-002 does not target the virus itself, instead targeting the immune response associated with the virus to stop the disease from progressing before it becomes fatal.

Newswise: Sanford Burnham Prebys researchers awarded $3.6 million to study antibiotic resistance
Released: 13-Jan-2022 5:35 PM EST
Sanford Burnham Prebys researchers awarded $3.6 million to study antibiotic resistance
Sanford Burnham Prebys

Sanford Burnham Prebys professor Andrei Osterman, Ph.D., has been awarded a $3.6 million grant from the National Institutes of Health (NIH) to expand current knowledge of antibiotic resistance, which will inform more precise antibiotic prescribing practices and help researchers develop drugs that are harder for bacteria to resist.

Newswise: Sanford Burnham Prebys strengthens executive leadership team
Released: 17-Dec-2021 1:00 PM EST
Sanford Burnham Prebys strengthens executive leadership team
Sanford Burnham Prebys

Sanford Burnham Prebys is pleased to announce several new appointments to its executive leadership team, fortifying the Institute’s position as a world leader in nonprofit biomedical research.

Released: 16-Nov-2021 3:05 AM EST
Sanford Burnham Prebys professors among the world’s most highly cited researchers
Sanford Burnham Prebys

Over the last decade, the publications of Jerold Chun and Randal J. Kaufman are among the top 1% in the world for number of citations

12-Nov-2021 5:05 PM EST
Sanford Burnham Prebys unravels mysteries of the aging Down syndrome brain
Sanford Burnham Prebys

New research from Sanford Burnham Prebys has revealed features of the aging Down syndrome brain that could help explain why people with Down syndrome almost inevitably get Alzheimer's later in life.

9-Nov-2021 6:05 PM EST
Study encourages cautious approach to CRISPR therapeutics
Sanford Burnham Prebys

Researchers from Sanford Burnham Prebys and the National Cancer Institute have shown that gene editing with CRISPR may select for certain cancer-associated mutations, highlighting the need for caution when using CRISPR therapeutically.

Released: 12-Oct-2021 8:35 AM EDT
New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease
Sanford Burnham Prebys

Researchers from Sanford Burnham Prebys have discovered a new source of stem cells just outside the liver that could help treat people living with Alagille syndrome, a rare, incurable genetic disorder in which the bile ducts of the liver are absent, leading to severe liver damage and death. The findings, published recently in the journal Hepatology, have extensive biomedical implications for Alagille syndrome and for liver disease in general, including cancer.

Newswise: Sanford Burnham Prebys awarded $13.5 million by NIH to investigate the pathogenesis and treatment of sepsis
Released: 23-Sep-2021 2:05 PM EDT
Sanford Burnham Prebys awarded $13.5 million by NIH to investigate the pathogenesis and treatment of sepsis
Sanford Burnham Prebys

Sanford Burnham Prebys professor Jamey Marth, Ph.D., has been awarded $13.5 million from the National Heart, Lung, and Blood Institute to continue his team’s work on sepsis, a condition that occurs when infectious and pathogenic organisms enter the bloodstream. This five-year award is a continuation of a multi-institution initiative, now totaling $27 million, that Marth began in 2016 with the goal of identifying the molecular basis of sepsis to achieve more effective treatments.

Newswise: Peter Adams and Gerald Shadel awarded $13 million from NIH to study aging and liver cancer
Released: 23-Sep-2021 12:40 PM EDT
Peter Adams and Gerald Shadel awarded $13 million from NIH to study aging and liver cancer
Sanford Burnham Prebys

Sanford Burnham Prebys professor Peter D. Adams, Ph.D., and Salk Institute professor Gerald Shadel, Ph.D., have been awarded a grant from the NIH’s National Institute on Aging for $13 million, funding a five-year project to explore the connection between aging and liver cancer.



close
0.12954